BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36018521)

  • 21. Lymph node yield is an independent predictor of survival in rectal cancer regardless of receipt of neoadjuvant therapy.
    Xu Z; Berho ME; Becerra AZ; Aquina CT; Hensley BJ; Arsalanizadeh R; Noyes K; Monson JRT; Fleming FJ
    J Clin Pathol; 2017 Jul; 70(7):584-592. PubMed ID: 27932667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with operable breast cancer and positive axillary nodes at initial diagnosis.
    Rebollo-Aguirre AC; Gallego-Peinado M; Sánchez-Sánchez R; Pastor-Pons E; García-García J; Chamorro-Santos CE; Menjón-Beltrán S
    Rev Esp Med Nucl Imagen Mol; 2013; 32(4):240-5. PubMed ID: 23684711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy.
    Beek MA; Tetteroo E; Luiten EJ; Gobardhan PD; Rutten HJ; Heijns JB; Voogd AC; Klompenhouwer EG
    Eur J Surg Oncol; 2016 May; 42(5):672-8. PubMed ID: 26898838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
    Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
    Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Breast Magnetic Resonance Imaging an Accurate Predictor of Nodal Status After Neoadjuvant Chemotherapy?
    Cortina CS; Gottschalk N; Kulkarni SA; Karst I
    J Surg Res; 2021 Jan; 257():412-418. PubMed ID: 32892139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Luminal A Breast Cancer: How Feasible is Omitting Axillary Dissection Without Neoadjuvant Therapy.
    Yüksel C; Aksel B; Doğan L
    Breast J; 2022; 2022():8284814. PubMed ID: 35974878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases.
    Uyan M; Koca B; Yuruker S; Ozen N
    Asian Pac J Cancer Prev; 2016; 17(3):1181-5. PubMed ID: 27039745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
    J Transl Med; 2018 Nov; 16(1):318. PubMed ID: 30454008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
    Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
    Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting lymph node yield in patients undergoing axillary node dissection for primary breast cancer: a single-institution review.
    Lee MC; Plews R; Rawal B; Kiluk JV; Loftus L; Laronga C
    Ann Surg Oncol; 2012 Jun; 19(6):1818-24. PubMed ID: 22203185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
    Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
    Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary reverse mapping (ARM) in clinically node positive breast cancer patients.
    Beek MA; Gobardhan PD; Klompenhouwer EG; Rutten HJ; Voogd AC; Luiten EJ
    Eur J Surg Oncol; 2015 Jan; 41(1):59-63. PubMed ID: 25468747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy.
    Almahariq MF; Levitin R; Quinn TJ; Chen PY; Dekhne N; Kiran S; Desai A; Benitez P; Jawad MS; Gustafson GS; Dilworth JT
    Ann Surg Oncol; 2021 Feb; 28(2):930-940. PubMed ID: 32712895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy.
    Kim H; Han J; Kim SY; Lee ES; Kang HS; Lee S; Jung SY; Lee E
    J Breast Cancer; 2021 Dec; 24(6):531-541. PubMed ID: 34979599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
    Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
    Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
    Cohen BL; Collier AL; Kelly KN; Goel N; Kesmodel SB; Yakoub D; Moller M; Avisar E; Franceschi D; Macedo FI
    Ann Surg Oncol; 2020 Jun; 27(6):1830-1841. PubMed ID: 31989360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
    Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
    Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons.
    Frasson AL; Resende HM; Lichtenfels M; Barbosa F; de Souza ABA; Miranda I; Falcone AB
    J Surg Oncol; 2020 Nov; 122(6):1247-1251. PubMed ID: 33045117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.